Testagen is a synthetic short peptide investigated in laboratory research as a molecular regulator of gene-expression programs associated with pituitary–thyroid axis signaling in preclinical experimental models. Published studies describe Testagen-associated modulation of transcriptional activity in endocrine tissues under controlled in-vivo and in-vitro conditions, with emphasis on regulatory interactions between pituitary-derived signaling factors and downstream endocrine-responsive gene networks.

Due to its low molecular weight and short amino-acid sequence, Testagen is examined as a research tool for probing peptide–DNA interactions, transcriptional regulation, and epigenetic mechanisms governing endocrine-system signaling in animal and cellular models.

Molecular Formula: C₁₇H₂₉N₅O₉
Molecular Weight: 447.2 g/mol

Source: PubChem

Testagen is utilized as a laboratory reagent in research programs focused on:

• transcriptional regulation within pituitary-derived endocrine signaling pathways,

• peptide-mediated modulation of thyroid-responsive gene-expression networks in animal models,

• investigation of peptide penetration across cellular and nuclear membranes,

• epigenetic regulation of genes involved in endocrine and immune-related differentiation pathways, and

• mechanistic studies of hemostasis-associated gene-expression regulation in preclinical systems.

Experimental evidence indicates that short regulatory peptides such as Testagen can penetrate cellular and nuclear membranes and associate with DNA regulatory regions. In preclinical models, this interaction has been linked to altered transcriptional activity of genes governing pituitary signaling and downstream thyroid-responsive pathways.

Within hypophysectomized avian models, Testagen-associated transcriptional modulation has been evaluated in the context of thyroid morphology, endocrine signaling intermediates, and systemic regulatory feedback mechanisms. These findings are interpreted through changes in gene-expression profiles rather than direct physiological outcomes.

Additional mechanistic studies describe peptide-driven regulation of differentiation-associated genes in stem and progenitor cell populations, supporting the use of Testagen as a molecular probe for studying lineage commitment and transcriptional plasticity under experimental conditions.

The peer-reviewed literature evaluating Testagen includes:

• avian models examining pituitary–thyroid signaling following experimental peptide exposure,

• cellular studies of peptide–DNA interactions and nuclear localization,

• investigations into transcriptional regulation of differentiation-associated genes, and

• experimental assessments of gene-expression changes related to immune-system lineage development and hemostasis-associated pathways.

All findings remain limited to controlled laboratory systems and established preclinical models.

Testagen is supplied as a synthetic peptide reagent intended for laboratory research use. Standard analytical characterization methods for peptide identity and purity may include chromatographic and mass-spectrometric techniques (e.g., HPLC and MS), with documentation provided according to supplier quality systems.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005). Vladimir Khavinson introduced scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries.

Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Testagen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Prof. Vladimir Khavinson is listed in [4] and [5] under the referenced citations.

1. B. I. Kuznik, A. V. Pateiuk, N. S. Rusaeva, L. M. Baranchugova, and V. I. Obydenko, “[Effects of hypophyseal Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly synthetic peptides on immunity, hemostasis, morphology and functions of the thyroid gland in neonatally hypophysectomized chicken and one-year-old birds],” Patol. Fiziol. Eksp. Ter., no. 1, pp. 14–18, Mar. 2010.
2. B. I. Kuznik, A. V. Pateiuk, N. S. Rusaeva, L. M. Baranchugova, and V. I. Obydenko, “[Effects of Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly peptides on hormonal activity and thyroid morphology in hypophysectomized mature and old birds],” Adv. Gerontol. Uspekhi Gerontol., vol. 24, no. 1, pp. 93–98, 2011.
3. A. W. Meikle, “The interrelationships between thyroid dysfunction and hypogonadism in men and boys,” Thyroid Off. J. Am. Thyroid Assoc., vol. 14 Suppl 1, pp. S17-25, 2004, doi: 10.1089/105072504323024552.
4. L. I. Fedoreyeva, I. I. Kireev, V. K. Khavinson, and B. F. Vanyushin, “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA,” Biochem. Biokhimii͡a, vol. 76, no. 11, Art. no. 11, Nov. 2011, doi: 10.1134/S0006297911110022.
5. V. Khavinson, N. Linkova, A. Diatlova, and S. Trofimova, “Peptide Regulation of Cell Differentiation,” Stem Cell Rev. Rep., vol. 16, no. 1, pp. 118–125, Feb. 2020, doi: 10.1007/s12015-019-09938-8.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.